CytomX Therapeutics (CTMX) Research & Development (2016 - 2025)
Historic Research & Development for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $15.3 million.
- CytomX Therapeutics' Research & Development fell 2837.89% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 2920.5%. This contributed to the annual value of $83.4 million for FY2024, which is 734.04% up from last year.
- Per CytomX Therapeutics' latest filing, its Research & Development stood at $15.3 million for Q3 2025, which was down 2837.89% from $13.3 million recorded in Q2 2025.
- CytomX Therapeutics' Research & Development's 5-year high stood at $36.6 million during Q4 2021, with a 5-year trough of $13.3 million in Q2 2025.
- For the 5-year period, CytomX Therapeutics' Research & Development averaged around $22.9 million, with its median value being $21.4 million (2024).
- Within the past 5 years, the most significant YoY rise in CytomX Therapeutics' Research & Development was 6621.98% (2021), while the steepest drop was 4774.84% (2021).
- Quarter analysis of 5 years shows CytomX Therapeutics' Research & Development stood at $36.6 million in 2021, then plummeted by 46.52% to $19.6 million in 2022, then decreased by 0.91% to $19.4 million in 2023, then decreased by 23.71% to $14.8 million in 2024, then rose by 3.48% to $15.3 million in 2025.
- Its Research & Development was $15.3 million in Q3 2025, compared to $13.3 million in Q2 2025 and $18.9 million in Q1 2025.